(Q44311446)

1 December 2017

title

Multiple sclerosis, interferon beta and clinical thyroid dysfunction (English)

1 reference

1 December 2017

0 references

A Kreisler

1

1 reference

1 December 2017

J de Seze

2

1 reference

1 December 2017

T Stojkovic

3

1 reference

1 December 2017

B Delisse

4

1 reference

1 December 2017

M Combelles

5

1 reference

1 December 2017

A Vérier

6

1 reference

1 December 2017

P Hautecoeur

7

1 reference

1 December 2017

P Vermersch

8

1 reference

1 December 2017

Groupe septentrional d'étude et de recherche sur la Sclérose en Plaques (G-SEP)

9

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Acta Neurologica Scandinavica

1 December 2017

published in

1 reference

1 December 2017

volume

107

1 reference

1 December 2017

issue

2

1 reference

1 December 2017

page(s)

154-157

1 reference

Interferon beta-1b injection site reactions and necroses

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Side effect profile of interferon beta-1b in MS: results of an open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Thyroiditis after treatment with interleukin-2 and interferon alpha-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

The neuroendocrine axis in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Autoimmune events during interferon beta-1b treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Long-term interferon beta-1b therapy for MS: is routine thyroid assessment always useful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Long-term treatment with interferon-beta therapy for multiple sclerosis and occurrence of Graves' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Autoimmune hypothyroidism associated with interferon beta-1b treatment in two patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Subacute thyroiditis in a patient with MS treated with interferon beta-1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Multiple sclerosis and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Early synthesis and correlation of serum anti-thyroid antibodies with clinical parameters in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Association of MS with thyroid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

Thyroid dysfunction and liver injury following alpha-interferon treatment of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

inferred from DOI database lookup

7 January 2021

based on heuristic

Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon-beta treatment

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

inferred from DOI database lookup

7 January 2021

based on heuristic

Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02009.X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1034/J.1600-0404.2003.02009.X

1 reference

1 December 2017

1 reference